RxDoctor Payments Data

Rebecca Gross, MD

Adolescent Medicine · Chevy Chase, MDNPI 1093763179

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 20 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Pfizer at 32.3% of the total.

$324in general payments, 2019–2025

Across 20 payments — averaging $16.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$104
  • Merck$51
  • AstraZeneca$50
  • Novo Nordisk$37
  • AbbVie$30
  • Teva Pharmaceuticals USA, Inc.$28
  • plus $24 from 1 others

What the payments were for

  • Food & beverage$324100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer7$104
Merck3$51
AstraZeneca3$50
Novo Nordisk2$37
AbbVie(2 entities)2$30
Teva Pharmaceuticals USA, Inc.2$28
Boehringer Ingelheim1$24

How this compares

$324 in reported general payments places this provider in the 65th percentile of 92 adolescent medicine providers in Maryland.

See all adolescent medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$86,712
Medicare patients
185
Services billed
858

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Atorvastatin Calcium92$1,747
Duloxetine Hcl11$755
SynthroidLevothyroxine Sodium16$700
Bupropion XlBupropion Hcl15$616
Rosuvastatin Calcium21$475
Levothyroxine Sodium44$423
Escitalopram Oxalate21$423
Lisinopril18$281
Metformin Hcl ErMetformin Hcl17$262
Sertraline Hcl15$260
Fluoxetine Hcl12$213
Amlodipine Besylate28$195
Losartan Potassium13$195
Simvastatin16$130
Atenolol11$129

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieSynthroid$30$70016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 92 adolescent medicine providers in Maryland.

Other adolescent medicine in Chevy Chase

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →